Reversibility of amyloid-induced mitochondrial dysfunction in Alzheimer’s disease

2019 Pilot Project Read More


Principal Investigator: Jin-Moo Lee (WashU Neurology)
Collaborator: Song Hu (WashU Biomedical Engineering)


Deficiency in brain energy metabolism has long been recognized as a prominent event in the development of Alzheimer’s disease. Recent studies provide new evidence that mitochondrial dysfunction may occur early and in proximity to amyloid deposition, a hallmark of Alzheimer’s disease. In this project, we seek to understand the spatiotemporal relationship between amyloid deposition and mitochondrial metabolic dysfunction through the development and application of first-of-a-kind dual-modal microscopy (i.e., multi-photon fluorescence microscopy of mitochondrial function and amyloid deposition at the cellular level and multi-parametric photoacoustic microscopy of oxygen metabolism at the tissue level) in a mouse model of Alzheimer’s disease. Examination of the potential reversibility of mitochondrial metabolic dysfunction following anti-amyloid therapies may lead to non-invasive imaging biomarkers that predict when such therapies can alter the course of neurodegeneration. Translation of such neuroimaging biomarkers to patients may one day guide therapeutic intervention.


Pilot project teams include Hope Center faculty members and others. For more about Hope Center faculty on this team, click below.

Jin-Moo Lee

Song Hu